Cyprotex launches new CNS-related service to assess brain tissue binding
Cyprotex are proud to announce the launch of an enhanced Cloe® Select experimental service to evaluate brain tissue binding - an important factor in determining CNS penetration. This service extends our range of CNS services to include MDR1-MDCK permeability, brain to plasma ratio studies, brain tissue binding and plasma protein binding. A combination of these assays is the recommended approach for evaluating CNS penetration in drug discovery (Reichel 2009 Chemistry and Biodiversity 6; 2030-2049). By implementing this integrated approach, a greater understanding of the link between exposure and efficacy for CNS therapies is achieved.
In addition to our experimental services, Cyprotex will also be launching a blood brain barrier predictive model in 2010 which will use experimental data to predict in vivo brain pharmacokinetics and pharmacodynamics.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments on the launch of the new brain tissue binding service. ‘Launching this new service allows us to keep up-to-date with current industry approaches in the evaluation of CNS therapies in drug discovery. We now offer a range of CNS-related services which can provide useful guidance in progressing compounds through the lead optimisation stage.’
For further information:
Helen Gill PhD, Product Development Manager
Tel: +44 (0)1625 505 100